metastatic-recurrent HNSCC (mHNSCC) | |||
mHNSCC - L2 - all population | mHNSCC - L2 - PDL1 negative | mHNSCC - L2 - PDL1 positive | |
immune chekpoint inhibitors | |||
anti-PD-(L)1 | |||
durvalumab based treatment | |||
durvalumab alone | EAGLE ... | ||
nivolumab based treatment | |||
nivolumab alone | CheckMate 141 | ||
pembrolizumab based treatment | |||
pembrolizumab alone | KEYNOTE-040 ... | KEYNOTE-040 ... | |
Immune checkpoint association | |||
durvalumab plus tremelimumab | EAGLE ... |